Akorn (AKRX) cleared an early 42.64 buy point Tuesday after announcing that the Food and Drug Administration had approved one of its new products. But volume was light as the stock broke out of an irregular base, making it risky to buy, especially with the market’s uptrend under pressure. Investors may choose to see if the stock can clear a proper entry at 45.35 in volume that’s at least 40% above normal.